# NUTM2D

## Overview
NUTM2D is a gene that encodes the protein NUT family member 2D, which is part of the NUT (nuclear protein in testis) family. This protein is involved in various cellular processes, although its specific functions remain to be fully elucidated. NUT family proteins are generally associated with chromatin regulation and transcriptional control, and they can play roles in cellular differentiation and proliferation. The NUTM2D gene has gained attention due to its involvement in gene fusion events, particularly in the context of certain pediatric cancers, where it may contribute to oncogenic processes (Hodder2024Benefits). Understanding the role of NUTM2D and its encoded protein is crucial for elucidating the molecular mechanisms underlying these malignancies and for developing targeted therapeutic strategies.

## Function


## Clinical Significance
The NUTM2D gene has been implicated in certain pediatric cancers through its involvement in gene fusion events. A notable example is the discovery of an ATNX1-NUTM2D gene fusion in an infant with a high-grade brain tumor. This fusion represents a distinct tumor entity that could not be classified by standard histology or other molecular assays, highlighting the potential of whole-genome sequencing (WGS) to uncover unique genetic mutations that may not be detectable through standard testing methods (Hodder2024Benefits). The identification of such fusions can provide significant clinical insights, influencing treatment decisions and aiding in the management of pediatric cancers by revealing unique genetic markers (Hodder2024Benefits).

The broader utility of WGS in routine clinical practice is emphasized by its ability to reveal unexpected germline cancer predispositions and provide opportunities for predisposition-directed therapy. This suggests that alterations in NUTM2D, such as gene fusions, could play a role in oncogenic transformations, contributing to the development of aggressive cancer types like NUT carcinoma, which is characterized by NUT gene rearrangements (Hodder2024Benefits).


## References


[1. (Hodder2024Benefits) Angus Hodder, Sarah M. Leiter, Jonathan Kennedy, Dilys Addy, Munaza Ahmed, Thankamma Ajithkumar, Kieren Allinson, Phil Ancliff, Shivani Bailey, Gemma Barnard, G. A. Amos Burke, Charlotte Burns, Julian Cano-Flanagan, Jane Chalker, Nicholas Coleman, Danny Cheng, Yasmin Clinch, Caryl Dryden, Sara Ghorashian, Blanche Griffin, Gail Horan, Michael Hubank, Phillippa May, Joanna McDerra, Rajvi Nagrecha, James Nicholson, David O’Connor, Vesna Pavasovic, Annelies Quaegebeur, Anupama Rao, Thomas Roberts, Sujith Samarasinghe, Iryna Stasevich, John A. Tadross, Claire Trayers, Jamie Trotman, Ajay Vora, James Watkins, Lyn S. Chitty, Sarah Bowdin, Ruth Armstrong, Matthew J. Murray, Catherine E. Hook, Patrick Tarpey, Aditi Vedi, Jack Bartram, and Sam Behjati. Benefits for children with suspected cancer from routine whole-genome sequencing. Nature Medicine, 30(7):1905–1912, July 2024. URL: http://dx.doi.org/10.1038/s41591-024-03056-w, doi:10.1038/s41591-024-03056-w. This article has 1 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41591-024-03056-w)